Battling low expectations and goliath rivals, Regeneron/Sanofi add positive Libtayo data in pursuit of blockbuster status
Latecomers Regeneron and Sanofi continue to claw their way forward in the tough PD-(L)1 market. Researchers for the checkpoint allies offered a positive pivotal snapshot of their PD-1 Libtayo early Tuesday, which could provide another boost in an oncology market dominated by Merck’s Keytruda and Bristol Myers’ Opdivo.
The research team journeyed out into a patient population with no approved therapy: basal cell carcinoma in patients whose disease had advanced beyond the reach of a Hedgehog pathway inhibitor — meaning Erivedge and Odomzo. Right now, that’s the end of the line in the treatment paradigm.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.